8-KOther EventsExhibits & Filings

GILEAD SCIENCES, INC. 8-K Report, Corporate Update (Jun 23, 2005)

Filed June 23, 2005For Securities:GILD

Summary

Gilead Sciences, Inc. (GILD) has filed an 8-K report on June 23, 2005, to announce the termination of its Development and License Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. concerning the co-developed influenza treatment and prevention drug, Tamiflu® (oseltamivir phosphate). This termination is based on an alleged material breach of the 1996 Agreement by Roche. If the termination becomes effective, Gilead would regain all licenses granted to Roche under the agreement, potentially allowing Gilead to re-assume control over the manufacturing and sales of Tamiflu. This event could significantly impact Gilead's future revenue streams and strategic direction concerning its antiviral portfolio. Investors should monitor the developments and potential legal proceedings arising from this termination notice.

Key Highlights

  • 1Gilead Sciences has issued a notice of termination to Roche for a material breach of the 1996 Development and License Agreement related to Tamiflu.
  • 2The termination pertains to the co-development and commercialization of the antiviral drug Tamiflu® (oseltamivir phosphate).
  • 3Roche currently holds exclusive rights to manufacture and sell Tamiflu worldwide under the agreement.
  • 4If the termination becomes effective, Gilead would regain all licenses granted to Roche, potentially allowing Gilead to reclaim control of Tamiflu.
  • 5The agreement stipulated that Roche pays Gilead a percentage of net revenues from Tamiflu sales, subject to certain cost reductions.
  • 6This action signifies a potential major shift in Gilead's relationship with Roche and its control over a key product.

Frequently Asked Questions

Gilead has issued the notice of termination due to an alleged material breach of the 1996 Development and License Agreement by Roche concerning the drug Tamiflu.

If the termination becomes effective, Gilead would regain all the licenses that were granted to Roche, which could allow Gilead to take back control of the manufacturing and commercialization of Tamiflu.

Tamiflu is a jointly developed antiviral medication for the treatment and prevention of influenza. Under the 1996 agreement, Roche has the exclusive rights to sell it globally, with Gilead receiving a percentage of net revenues. This termination notice suggests a major dispute over the terms of this lucrative partnership.

The 8-K filing indicates that Gilead delivered the notice of termination on June 23, 2005. The effectiveness of the termination and the subsequent reversion of licenses to Gilead depend on the terms of the agreement and potentially any legal recourse Roche might take in response to the alleged breach.